Search
Paricalcitol
go.drugbank.com/drugs/DB00910ApprovedInvestigationalParicalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels.
Categories: Vitamin D and Analogues, Cytochrome P-450 SubstratesSynonyms: 19-Nor-1alpha,25-dihydroxyvitamin D2Metformin
go.drugbank.com/drugs/DB00331ApprovedInvestigationalMetformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes. … It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels.
Mixtures: JARDIANCE DUO® 5 MG/1000 MG, JARDIANCE DUO® 5 MG / 850 MGCategories: Drugs Used in Diabetes, MATE 1 SubstratesTofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: JANTY 5 MG FİLM KAPLI TABLET, 56 ADET, TOFİK 5 MG FİLM KAPLI TABLET, 56 ADETLevofloxacin
go.drugbank.com/drugs/DB01137ApprovedInvestigational[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663] … Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin].
Mixtures: TRILEVO 500 MG+30 MG+ 1000 MG TEDAVİ PAKETİCategories: 4-Quinolones, MATE 1 InhibitorsZidovudine
go.drugbank.com/drugs/DB00495ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. … The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription.
Mixtures: N/A, COMBİVİR 150 MG/300 MG FİLM KAPLI TABLETCategories: Antivirals used in combination for the treatment of HIV infections, Cytochrome P-450 SubstratesLenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigational[A228553] It is a 4-amino-glutamyl analogue of [thalidomide] [A228543] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. … contain an imide group.
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingSynonyms: 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dioneAtracurium besylate
go.drugbank.com/drugs/DB00732ApprovedA non-depolarizing neuromuscular blocking agent with short duration of action. … Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents
Categories: Heterocyclic Compounds, 2-RingProducts: DEMATRAC 50 MG/5 ML İNFÜZYON İÇİN SOLÜSYON İÇEREN AMPUL, 10 AMPUL, ATRASYL 50 MG/5 ML I.V. ENJEKSIYON VE INFÜZYON IÇIN ÇÖZELTI IÇEREN AMPUL , 10 AMPULFerric carboxymaltose
go.drugbank.com/drugs/DB08917ApprovedInvestigationalFerric carboxymaltose is an iron replacement product and, chemically, an iron-carbohydrate complex. It was FDA approved on July 25, 2013.
Categories: Compounds used in a research, industrial, or household settingProducts: Ferapplic 500 mg/10 ml Enjeksiyonluk/İnfüzyonluk Çözelti, 5 flakon, Ferinject® 50 mg iron/mL solution for injection/infusionIsotretinoin
go.drugbank.com/drugs/DB00982ApprovedInvestigationalIsotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne. … [L6579] The first isotretinoin-containing product was FDA approved on 7 May 1982.[L6574]
Mixtures: ISOTREXIN JEL, 30 G, ETREXİN % 2 + % 0.05 JELCategories: Retinoids for Topical Use in Acne, Cytochrome P-450 SubstratesDihydrocodeine
go.drugbank.com/drugs/DB01551ApprovedIllicitIt is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis … It was marketed in 1911.
Mixtures: Poly-tussin EX, J-cof DhcCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates